Harrison.ai, a healthcare technology company, has expedited the expansion of its operations into the US market, supported by a $112m Series C funding round.

This investment will also enhance the company's product development and support its continued growth across the UK, EMEA, and APAC regions.

To date, Harrison.ai has raised more than $240m in capital.

The company's technology is revolutionising radiology and pathology by assisting clinicians in the early detection of cancer and other critical illnesses.

Using artificial intelligence (AI), Harrison.ai analyses X-rays, CT scans, and pathology slides, enabling faster detection and diagnosis of medical conditions.

Harrison.ai co-founder and CEO Dr Aengus Tran said: “The growing demand for equitable and effective healthcare calls for advanced systems like AI to enhance human diagnostics and address disparities in access to care.

“Harrison.ai meets this need by developing clinical-grade AI models designed to improve capacity. We look forward to bringing our life-saving technology to healthcare systems in the US and continuing our expansion across the globe.”

Addressing the worldwide shortage of 1.5 million skilled clinicians, Harrison.ai is set to tackle the increasing demand for diagnosis, affecting both advanced and developing healthcare systems.

Harrison.ai's solutions enable improvements in early lung cancer detection within hospital systems.

Its radiology solution, Annalise.ai, is used by half of the radiologists in Australia, and processes scans for over 45 Trusts and more than 131 UK public hospitals, handling 35% of England’s chest X-ray volume.

In addition, the technology is implemented in all CT Brain scans across public accident and emergency systems in Hong Kong, and has recently been adopted by the Danish public healthcare system to improve clinical outcomes.

To further its global commercialisation efforts, Harrison.ai is establishing a presence in North America with a new office in Boston.